Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$25.00 USD
-1.12 (-4.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $25.01 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.00 USD
-1.12 (-4.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $25.01 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum B VGM
Zacks News
Here's Why You Should Bet on Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across its segments and prudent acquisitions.
BD Introduces New Product to Reduce the Risk of Sepsis
by Zacks Equity Research
BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.
Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
Strong prospects in emerging markets provide DENTSPLY (XRAY) a competitive edge in the MedTech space.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Dentsply (XRAY) Up 18.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Momentum Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st
XRAY vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Will DENTSPLY SIRONA Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DENTSPLY SIRONA.
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Earnings Preview: Dentsply International (XRAY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Near-Term Outlook for Dental Supplies Industry Looks Bright
by Zacks Equity Research
The wave of digital transformation is shaping the future of dental supply companies.
Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.
Why Is Dentsply (XRAY) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for December 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.
Dentsply International (XRAY) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -15.56% and -2.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
Dentsply (XRAY) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDCO or XRAY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. XRAY: Which Stock Is the Better Value Option?
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance
by Zacks Equity Research
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.